Valuation: MaaT Pharma

Market Cap 50.88M 58.14M 46.89M 43.46M 82.5M 5.52B 83.83M 562M 219M 2.72B 218M 214M 9.41B P/E 2026 *
-1.41x
P/E 2027 * -2.43x
Enterprise Value 62.18M 71.06M 57.31M 53.12M 101M 6.74B 102M 687M 267M 3.33B 267M 261M 11.5B EV / Sales 2026 *
6.38x
EV / Sales 2027 * 2.96x
Free-Float
36.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MaaT Pharma

1 day-1.46%
1 week+13.45%
Current month+13.45%
1 month-5.59%
3 months-50.09%
6 months-50.91%
Current year-43.87%
1 week 2.36
Extreme 2.36
3.14
1 month 2.32
Extreme 2.32
3.14
Current year 2.32
Extreme 2.32
8.62
1 year 2.32
Extreme 2.32
8.62
3 years 2.32
Extreme 2.32
9.96
5 years 2.32
Extreme 2.32
14.4
10 years 2.32
Extreme 2.32
14.4
Manager TitleAgeSince
Chief Executive Officer - 2013-12-31
Director of Finance/CFO 59 2024-10-31
Chief Tech/Sci/R&D Officer - 2024-06-23
Director TitleAgeSince
Director/Board Member 56 2013-12-31
Director/Board Member 64 2020-07-15
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
05-27Buy

Founder

2,000 0.0106%
01-28
Seventure Partners SA
SellCompany 25,423 0.1356%
01-27
Seventure Partners SA
SellCompany 57,964 0.3091%
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%+13.45%-46.64%-59.70% 58.95M
-0.10%+0.10%+74.33%+133.26% 57.73B
-3.80%-6.24%+67.04%+86.36% 54.69B
+1.17%+5.83%+16.39%+468.18% 24.18B
+0.38%+1.33%-14.32%-11.76% 23.75B
-1.31%+4.86%+44.83%-4.02% 19.82B
+3.78%+5.65%+44.99%-26.23% 17.14B
+3.46%+17.72%+206.66%+364.07% 16.75B
-7.00%+9.67%+35.75% - 15.57B
+2.79%+4.91%+29.26%+195.60% 13.96B
Average -0.21%+6.20%+45.83%+127.30% 24.36B
Weighted average by Cap. -0.61%+2.61%+57.86%+139.22%

Financials

2026 *2027 *
Net sales 9.75M 11.14M 8.99M 8.33M 15.81M 1.06B 16.07M 108M 41.9M 522M 41.83M 40.93M 1.8B 28.88M 33M 26.61M 24.67M 46.83M 3.13B 47.58M 319M 124M 1.55B 124M 121M 5.34B
Net income -31.69M -36.22M -29.21M -27.07M -51.39M -3.44B -52.22M -350M -136M -1.7B -136M -133M -5.86B -15.31M -17.5M -14.11M -13.08M -24.83M -1.66B -25.23M -169M -65.8M -820M -65.69M -64.26M -2.83B
Net Debt 11.3M 12.92M 10.42M 9.66M 18.33M 1.23B 18.63M 125M 48.58M 605M 48.5M 47.45M 2.09B 34.5M 39.42M 31.79M 29.47M 55.94M 3.74B 56.84M 381M 148M 1.85B 148M 145M 6.38B
Logo MaaT Pharma
MaaT Pharma is a late-stage biotechnology company and a leader in the development of intestinal microbiota-based drugs designed to modulate the immune system of cancer patients and improve their survival. A pioneer in its field, MaaT Pharma is developing the first immunomodulatory drug candidate based on intestinal microbiota in oncology, currently in phase 3 clinical evaluation. Thanks to its proprietary pooling (combining donations of healthy microbiota) and microbial co-culture technologies, MaaT Pharma is developing standardised drugs with high bacterial diversity, aimed at improving the survival of cancer patients.
Employees
56
Date Price Change Volume
26-07-07 €2.700 -1.46% 24,577
26-07-06 €2.740 -4.86% 95,929
26-07-03 €2.880 +9.09% 248,148
26-07-02 €2.640 +11.86% 64,545
26-07-01 €2.360 -0.84% 41,840
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.700EUR
Average target price
6.500EUR
Spread / Average Target
+140.74%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MAAT Stock